AVBP vs. RYTM, INDV, GERN, BHC, JANX, DCPH, MRVI, RCKT, AMRX, and VERA
Should you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Rhythm Pharmaceuticals (RYTM), Indivior (INDV), Geron (GERN), Bausch Health Companies (BHC), Janux Therapeutics (JANX), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), Rocket Pharmaceuticals (RCKT), Amneal Pharmaceuticals (AMRX), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical preparations" industry.
Rhythm Pharmaceuticals (NASDAQ:RYTM) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
ArriVent BioPharma has a net margin of 0.00% compared to ArriVent BioPharma's net margin of -297.91%. Rhythm Pharmaceuticals' return on equity of 0.00% beat ArriVent BioPharma's return on equity.
9.5% of ArriVent BioPharma shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
ArriVent BioPharma has lower revenue, but higher earnings than Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals received 268 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 65.71% of users gave Rhythm Pharmaceuticals an outperform vote.
In the previous week, ArriVent BioPharma had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for ArriVent BioPharma and 4 mentions for Rhythm Pharmaceuticals. ArriVent BioPharma's average media sentiment score of 0.60 beat Rhythm Pharmaceuticals' score of 0.21 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.
Rhythm Pharmaceuticals currently has a consensus target price of $54.33, indicating a potential upside of 35.94%. ArriVent BioPharma has a consensus target price of $29.25, indicating a potential upside of 57.68%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Rhythm Pharmaceuticals.
Summary
ArriVent BioPharma beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get ArriVent BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ArriVent BioPharma Competitors List
Related Companies and Tools
